Table 1 Clinical and epidemiological characteristics of seronegative individuals, EHI patients, RPs, and TPs
NCs N = 11 | EHI N = 29 | RPs N = 18 | TPs N = 11 | P (Pa/ Pb) | |
|---|---|---|---|---|---|
Age, years | 31 (28–35) | 28 (22–39) | 37 (23–42) | 25 (22–35) | NS/NS |
Han ethnicity, no., (%) | 11 (100 %) | 29 (100 %) | 18 (100 %) | 11 (100 %) | NS/NS |
Male gender, no., (%) | 11 (100 %) | 29 (100 %) | 18 (100 %) | 11 (100 %) | NS/NS |
Follow-up days, days | NA | 1149 (862–1297) | 1091 (821–1311) | 1171 (990–1284) | NA/NS |
At baseline | |||||
Estimated time at baseline, days | NA | 55 (36–100) | 69 (35–102) | 53 (37–81) | NA/NS |
Baseline CD4 + T cell counts, cells/μL | 728 (568–876) | 490 (312–568) | 337 (265–520) | 586 (499–685) | 0.015/0.000 |
Baseline HIV-1 RNA load, log10 copies/mL | NA | 4.70 (3.78–5.50) | 5.02 (4.24–5.78) | 4.03 (3.06–5.15) | NA/NS |
At 12-month follow-up visit | |||||
CD4 + T cell counts, cells/μL | NA | 329 (271–539) | 298 (239–328) | 599 (525–732) | NA/0.000 |
HIV-1 RNA load, log10 copies/mL | NA | 4.50 (3.64–4.85) | 4.55 (3.19–4.85) | 4.45 (3.73–4.91) | NA/0.902 |
At primary endpoint | |||||
Estimated time at primary endpoint, days | NA | 340 (104–1149) | 123 (79–272) | 1171 (990–1284) | NA/0.000 |
CD4 + T cell counts, cells/μL | NA | 321 (281–467) | 311 (274–342) | 422 (309–541) | NA/0.027 |
HIV-1 RNA load, log10 copies/mL | NA | 4.59 (3.89–5.27) | 4.59 (3.79–4.71) | 4.49 (3.88–5.37) | NA/0.152 |